drugtrek.com

DrugTrek PC is a micro small-to-medium enterprise (SME) and a BSRC Fleming and Uni-Pharma SA spinoff founded in 2025.

DrugTrek PC was created following years of collaboration between the BSRC Fleming, a leading Research Institute in Greece, and Uni-Pharma SA, one of the largest pharmaceutical companies in Greece.
DrugTrek PC is dedicated to the discovery and development of novel therapeutics targeting fibrotic diseases, with a primary focus on idiopathic pulmonary fibrosis (IPF).
The company has established a robust drug discovery pipeline that integrates chemoinformatics, structure-based design, and translational pharmacology to generate first-in-class small molecules. The collaborative research and development of BSRC Fleming and Uni-Pharma SA on Autotaxin have led to an extensive intellectual property (IP) portfolio and promising clinical candidates for the treatment of IPF and other ILDs, an unmet medical need. DrugTreks' ambition is to bring new drug molecules to the clinic and alleviate the heavy societal toll of fibrosis.
DrugTrek’s main offices are located at the Patras Science Park (PSP). DrugTrek PC is uniquely positioned to deliver a transformative therapeutic solution for fibrotic diseases and implement the clinical translation of innovative research results.